SURVYR

RAPP

Rapport Therapeutics, Inc.
$26.34
−$3.03 (10.32%)Oct 21 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-10%+17%+45%+73%+100%Oct 2025Oct 2026Apr 202652w high $52.9352w low $23.75
RAPPSPY
Wall St. Highest PT $91.00 (+245.5%) Wall St. Avg PT $64.97 (+146.7%)
$24$48$72$95$119POC $27Hi $91Avg $65
Underwater Drawdown %Max DD -49.8%Current -49.8%
0.0%-49.8%
Relative Strength vs SPY-16.7% vs SPYUnderperforming
+96%0%-96%
1W
−$1.99 (7.02%)
1M
−$13.32 (33.59%)
3M
−$14.99 (36.27%)
6M
−$10.44 (28.38%)
YTD
−$4.00 (13.18%)
1Y
−$0.44 (1.64%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
15 analysts · mean score 1.06
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$26.34
Average target$64.97
+$38.63 (+146.7%) upsideaverage target vs current price
CurrentAverageMedian
Low$50.00
Median$64.97
High$91.00
12-month Wall Street target range
Recent analyst rating changes · 8
Reiterated
2026-10-21 · Wells Fargo reiterated Overweight on RAPP
Reiterated
2026-10-21 · Guggenheim reiterated Buy on RAPP
Reiterated
2026-10-20 · HC Wainwright & Co. reiterated Buy on RAPP
Reiterated
2026-10-20 · BTIG reiterated Buy on RAPP
Initiated
2026-10-15 · UBS started covering RAPP at Buy
Initiated
2026-10-15 · Wolfe Research started covering RAPP at Outperform
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$1.3B
P/E (next 12 months, estimated)-5.2
52-week range$23.75 – $52.93
Dividend yieldNo dividend
Analyst consensusStrong Buy (15)
Average analyst price target$64.97 (+147%)

What they do

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for RAPP yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

RAPP earningsNext report in 8 days
Next report · quarter Sep 2026
Thu Nov 5, 2026Before the open
EPS consensus-$1.22 range -$1.36–-$1.08
Revenue consensus$0 14 analysts
Last 4 quarters · EPS vs estimate
Aug 5, 2026-$1.19est -$0.99−20.4%Below estimates
May 7, 2026-$0.42est -$0.71+40.7%Above estimates
Mar 10, 2026-$0.72est -$0.67−6.8%Below estimates
Nov 6, 2025-$0.71est -$0.73+3.0%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-21 12:05:23 ET
24-1125-0325-0525-0825-1126-0326-0526-08-1.190.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$0–
2026-03-31$20.0M–
2025-12-31$0–
2025-09-30$0–
2025-06-30$0–

News & catalysts

More news
Rapport Therapeutics Enters Oversold Territory (RAPP)
Nasdaq · Oct 21
Rating changes
Reiterated
2026-10-21 · Wells Fargo reiterated Overweight on RAPP
Reiterated
2026-10-21 · Guggenheim reiterated Buy on RAPP
Reiterated
2026-10-20 · HC Wainwright & Co. reiterated Buy on RAPP
Reiterated
2026-10-20 · BTIG reiterated Buy on RAPP
Initiated
2026-10-15 · UBS started covering RAPP at Buy
Initiated
2026-10-15 · Wolfe Research started covering RAPP at Outperform

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Sanchez Ramiro
Director · 2026-10-23
Buy
$98.5K
Maraganore John
Director · 2026-10-22
Buy
$31.5K
Maraganore John
Director · 2026-10-22
Buy
$217.3K
Paul Steven M
Director · 2026-10-22
Buy
$974.3K
Young Wendy B.
Director · 2026-10-22
Buy
$100.0K
Silva Paul M
Director · 2026-10-22
Buy
$99.6K
Ignelzi Troy A.
Chief Financial Officer · 2026-10-21
Buy
$143.6K
Ceesay Abraham
Director, Chief Executive Officer · 2026-10-21
Sell
$64.4K
Ceesay Abraham
Director, Chief Executive Officer · 2026-10-07
Sell
$35.2K
Ceesay Abraham
Director, Chief Executive Officer · 2026-10-06
Sell
$108.1K
Gault Cheryl
Chief Operating Officer · 2026-09-30
Sell
$70.0K
Gault Cheryl
Chief Operating Officer · 2026-09-30
Sell
$261.8K

Stats refreshed 2026-10-21 12:05:23 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026